Umbilical Cord Blood Therapy for Children With Global Developmental Delay
This open-label study aims to evaluate the safety and efficacy of autologous or allogeneic umbilical cord blood therapy for children with global developmental delay.
NCT01769716 — Global Developmental Delay
Status: Completed
http://inclinicaltrials.com/global-developmental-delay/NCT01769716/
Unrelated Umbilical Cord Blood (UCB) Transplantation
Hematopoietic progenitor cell (HPC- primitive cells in the blood, bone marrow and umbilical cord that can restore the bone marrow) transplant can be a curative therapy for the treatment of hematologic malignancies (a disease of the bone marrow and lymph nodes). The source of cells used for the transplant comes from related (sibling) and in cases where there is no sibling match, from unrelated donors through the National Marrow Donor Program. The availability of a suitable donor can be a significant obstacle for patients who need a transplant but do not have a matched donor. Cord blood that has been harvested from an umbilical cord shortly after birth has a rich supply of cells needed for transplant. These stored cord bloods are now being used to transplant adults without a matched donor Advantages to using cord blood includes a readily available source of cells with no risk to the donor during the collection process, immediate source of cells in urgent situations (no lengthy donor work-up)and a reduction in infectious disease transmission to the recipient. One of the main disadvantages is the cord blood has a small number of cells needed for transplant. In an adult, usually two cords are needed and large recipients do not qualify because they need too many cells. This study will use two different preparative regimens (chemotherapy and radiation) followed by one or two umbilical cord units (UBC). The preparative regimen used will be chosen by the physician and is based on patient's age, disease and medical condition at the time of transplant. Multiple objectives for this study include disease-free and overall survival, treatment related mortality, rate of cells taking hold, and the incidence and severity of the transplant complication called graft versus host disease (GVHD).
NCT01768845 — Multiple Myeloma
Status: Completed
http://inclinicaltrials.com/multiple-myeloma/NCT01768845/
Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure Following Autologous Hematopoietic Stem Cell Transplantation
The purpose of this study is to evaluate the utility of treating patients experiencing graft failure after autologous hematopoietic stem cell transplantation with ex-vivo-expanded BM-drived mesenchymal stem cells from third-party donors or mesenchymal stem cells combined with cord blood. The first objective of this study was to evaluate the effect of such treatment on graft failure, and second object was to investigate the safety of such treatment.
NCT01763099 — Hematopoietic Stem Cell Transplantation
Status: Recruiting
http://inclinicaltrials.com/hematopoietic-stem-cell-transplantation/NCT01763099/
Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
The purpose of this study is to determine whether Eltrombopag may shorten time to platelet engraftment after allogeneic cord blood transplantation.
NCT01757145 — Hematological Malignancy
Status: Recruiting
http://inclinicaltrials.com/hematological-malignancy/NCT01757145/
The Collection and Storage of Umbilical Cord Blood for Transplantation
The goal of this study is to collect blood samples from the umbilical cords of newborn babies, as soon as they are delivered, and to place these samples in the MD Anderson Cord Blood Bank. Your sample may be included in the National Cord Blood Inventory (NCBI) which is part of the CW Bill Young Cell Transplantation Program. The NCBI is a federally-supported program to assist in the collection of cord blood. Cord blood will be made available to patients through The National Marrow Donor Program (NMDP). These samples may then be offered to MD Anderson and other institutions for patients who need a bone marrow transplant and do not have a donor. The MD Anderson Cord Blood Bank will have the rights to release cord blood units to these institutions around the world according to established bone marrow transplant donor criteria, for a fee to cover costs. Cord blood samples that are collected and then do not meet the clinical requirements for patient use may also be used at MD Anderson or other institutions either for research or for quality purposes to improve cord blood banking procedures. If not suitable for patient use or for research purposes, the cord blood unit may be thrown away.
NCT01728545 — Hematopoietic Stem Cell Transplantation
Status: Recruiting
http://inclinicaltrials.com/hematopoietic-stem-cell-transplantation/NCT01728545/
Safety of Autologous Human Umbilical Cord Blood in the Treatment of Stroke in Children.
The specific aims of this study are: 1. To determine if Human Umbilical Cord Blood (hUCB) infusion is safe in children with perinatal arterial ischemic stroke (AIS). 2. To determine if late functional outcome, physiologic response, and anatomic findings are changed following hUCB infusion in children with perinatal AIS.
NCT01700166 — Arterial Ischemic Stroke (AIS) in Children
Status: Withdrawn
http://inclinicaltrials.com/arterial-ischemic-stroke-ais-in-children/NCT01700166/
Phase 1 Clinical Trial to Establish the Safety and Feasibility of Transplants of Umbilical Cord Blood Mononuclear Cells in Chronic Ischemic Stroke
The study is to assess the safety and possible efficacy of umbilical cord blood mononuclear cells (UCBMC) treatment of chronic ischemic stroke.
NCT01673932 — Stroke
Status: Recruiting
http://inclinicaltrials.com/stroke/NCT01673932/
Hematopoietic Stem Cell Transplantation Using Alternate Donor Umbilical Cord Blood Options
This study will determine the safety and applicability of experimental forms of umbilical cord blood (UCB) transplantation for patients with high risk hematologic malignancies who might benefit from a hematopoietic stem cell transplant (HSCT) but who do not have a standard donor option (no available HLA-matched related donor (MRD), HLA-matched unrelated donor (MUD)), or single UCB unit with adequate cell number and HLA-match).
NCT01652014 — Recurrent Mantle Cell Lymphoma
Status: Withdrawn
http://inclinicaltrials.com/recurrent-mantle-cell-lymphoma/NCT01652014/
Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy: Phase I Study of Feasibility and Safety
This is a pilot study to test feasibility and safety of collection, preparation and infusion of a baby's own (autologous) umbilical cord blood during the first 3 days of age if the baby is born with signs of brain injury. The cord blood used is fresh (not frozen and then thawed).
NCT01649648 — Hypoxic Ischemic Encephalopathy
Status: Completed
http://inclinicaltrials.com/hypoxic-ischemic-encephalopathy/NCT01649648/
Allogeneic Umbilical Cord Blood Therapy for Children With Cerebral Palsy
This study aims to evaluate the efficacy of umbilical cord blood therapy for children with cerebral palsy.
NCT01639404 — Cerebral Palsy
Status: Completed
http://inclinicaltrials.com/cerebral-palsy/NCT01639404/